^
    Back
    Association details:
    Biomarker:EGFR mutation + ER positive
    Cancer:HER2 Negative Breast Cancer
    Drug:Ibrance (palbociclib) (CDK4/6 inhibitor) +
    gedatolisib (PF-05212384) (mTOR inhibitor, PI3K inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    Biomarker analysis from a phase I study using gedatolisib+palbociclib+hormone therapy in ER+/HER2- metastatic breast cancer (mBC).

    Published date:
    05/13/2020
    Excerpt:
    Plasma sample analysis (n = 21) showed that pts with somatic alterations in EGFR (n = 4) had a greater response to therapy (p = 0.066), compared with pts without somatic EGFR alterations.
    Secondary therapy:
    fulvestrant
    DOI:
    10.1200/JCO.2020.38.15_suppl.1052
    Trial ID:
    B2151009